Fundz
New|Fundz now works inside Claude2 min

AI made execution free. Knowing first is the whole game now.

The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Dr Lal PathLabs acquires 70% stake in SN Genelab

PRIVATESep 24, 2026

Acquiring Company

Dr. Lal PathLabs Limited

Acquired Company

SN Genelab Private Limited

IndiaGujaratBiotechnologyHealth CareMedicalHealth DiagnosticsBiotechnologyHealth CareGeneticsHealth Diagnostics

Description

Dr Lal PathLabs has announced the acquisition of a 70% stake in SN Genelab Private Limited for up to Rs.168 crore, with an additional earn-out of Rs.31.5 crore. This strategic acquisition will allow Dr Lal PathLabs to expand its diagnostics portfolio and strengthen its market presence. Following this deal, SN Genelab will become a subsidiary of Dr Lal PathLabs.

Company Information

Company

Dr. Lal PathLabs Limited

Location

India

About

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. As of 31 March 2023, the company has 277 clinical laboratories, 5,102 patient service centers (PSCs) and 10,938 pick-up points (PUPs).

Fundz sees it the moment Dr. Lal PathLabs Limited makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Dr. Lal PathLabs Limited's next move

Learn about Strategic plan

Frequently asked

Who acquired SN Genelab Private Limited?

SN Genelab Private Limited was acquired by Dr. Lal PathLabs Limited, based in India. The deal was reported on September 24, 2026. Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Dr. Lal PathLabs Limited is privately held and operates in Biotechnology.

When did Dr. Lal PathLabs Limited acquire SN Genelab Private Limited?

Dr. Lal PathLabs Limited's acquisition of SN Genelab Private Limited was reported on September 24, 2026. Dr Lal PathLabs has announced the acquisition of a 70% stake in SN Genelab Private Limited for up to Rs.168 crore, with an additional earn-out of Rs.31.5 crore. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does SN Genelab Private Limited do?

SN Genelab Private Limited is a private limited company engaged in medical testing and diagnostics. It is known for providing various laboratory services to healthcare providers. Following the acquisition, it will operate as a subsidiary of Dr Lal PathLabs. It is privately held, operating in Biotechnology, and is based in Gujarat.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.